title: Frequency and antibiogram of multi-drug resistant Pseudomonas aeruginosa.
abstract: OBJECTIVE
  To find out the frequency and susceptibility pattern of multi-drug resistant (MDR) Pseudomonas aeruginosa in clinical specimens.
  
  
  METHODS
  Cross-sectional observational study.
  
  
  METHODS
  Department of Microbiology, Army Medical College, National University of Sciences and Technology (NUST), Rawalpindi, from January to September 2010.
  
  
  METHODS
  Routine clinical specimens were subjected to standard microbiological procedures and the isolates were identified to the species level. The antibiotics susceptibility was determined by Kirby Bauer Disc diffusion method and the results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines.
  
  
  RESULTS
  The frequency of MDR Pseudomonas aeruginosa among all the Pseudomonas aeruginosa strains isolated was found to be 22.7%. These isolates were most sensitive to Colistin followed by Piperacillin-Tazobactam and Cefoperazone-Sulbactum.
  
  
  CONCLUSIONS
  Increasing fequency of infections due to MDR Pseudomonas aeruginosa is an emerging threat in our set up which an be prevented by prescribing antibiotics judiciously and by adopting proper disinfection measures.
authors.affiliation: Department of Microbiology, Army Medical College, National University of Sciences and Technology, Islamabad. maria2283@gmail.com
authors.forename: Maria Mushtaq
authors.initials: MM
authors.lastname: Gill
authors.forename: Javaid
authors.initials: J
authors.lastname: Usman
authors.forename: Fatima
authors.initials: F
authors.lastname: Kaleem
authors.forename: Afreenish
authors.initials: A
authors.lastname: Hassan
authors.forename: Ali
authors.initials: A
authors.lastname: Khalid
authors.forename: Rabia
authors.initials: R
authors.lastname: Anjum
authors.forename: Qanita
authors.initials: Q
authors.lastname: Fahim
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002438:Cefoperazone / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology; D003430:Cross-Sectional Studies; D052978:Disk Diffusion Antimicrobial Tests / Q000295:instrumentation* / Q000379:methods; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D004791:Enzyme Inhibitors; D006801:Humans; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D013407:Sulbactam / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D000077725:Piperacillin, Tazobactam Drug Combination; D002438:Cefoperazone; D010397:Penicillanic Acid; D013407:Sulbactam; D010878:Piperacillin; D003091:Colistin